New Investigators
Nicolas Chomont, PhD
Theme 1 Principal Leader
& Scientific Director
Cecilia Costiniuk, MD
Theme 2 Co-Leader
Knowledge Mobilization Champion
Thomas T. Murooka, PhD
Theme 2 Co-Leader
Zabrina Brumme, PhD
Theme 1 Co-Participant
Christina Guzzo, PhD
Theme 1 Co-Participant
Mohammad-Ali Jenabian DVM, PhD
Theme 2 Co-Participant
Jerome Estaquier, PhD
Theme 2 Co-Participant
Keith Fowke, PhD
Theme 2 Co-Participant
EDI Champion
Jean-Pierre Routy, MD
Theme 3 Co-Participant
Research Institute McGill University Health Center
Élie Haddad, MD & PhD
Theme 3 Co-Participant
Research Center CHU Ste-Justine University of Montreal
Guy Sauvageau, MD & PhD
Theme 3 Co-Participant
Stem Cells Research Unit, IRIC, University of Montreal​
Scientific Advisory Board (SAB)
CanCURE 3.0 is guided by a Scientific Advisory Board comprising three world-renowned basic and clinical scientists with a proven track record in the field of HIV Cure research.
Mirko Paiardini, PhD
Division Chief for Microbiology and Immunology
Professor, Pathology and Laboratory Medicine, Emory School of Medicine,
Principal Investigator ERASE HIV
Co-Director, Next Generation Therapeutics Scientific Working Group
Center for AIDS Research
Emory National Primate Research Center, Emory University
Professor of Immunology,
Associate Dean of Biomedical Sciences
Memorial University of Newfoundland and Labrador
​
​
Michael Grant, PhD
Community Advisory Board (CAB)
.png)
Team Coordination
Partners
ViiV Healthcare
Born out of a partnership between GSK and Pfizer in 2009, with Shionogi joining in 2012, ViiV Healthcare is determined to help end the HIV epidemic. Their one focused goal unites 1100 employees located across over 20 countries, with their expertise in research, manufacturing, policy and more. Viiv's current portfolio of 14 HIV treatments is thier first step in fighting back against the disease. ViiV Healthcare is dedicated to widening access to ensure those who need their medicines can receive them. Collaborations with organisations such as IAS, CHAI and MPP enable their medicines to make the greatest possible impact in countries around the world.
Gilead
Gilead's focuses on advancing the care of patients through its research and development efforts directly impacts our relationships with physicians, patients and their caregivers, and our employees. They provide physicians with the resources to better care for their patients by rapidly and efficiently discovering and developing innovative therapeutics. They collaborate with patient advocates, design drugs to enhance treatment regimens and implement effective patient assistance programs to ensure our efforts help meet the needs of patients and their caregivers.
Merck
Merck's vision is to make a difference in the lives of people globally through their innovative medicines, vaccines, and animal health products. They are committed to being the premier, research-intensive biopharmaceutical company and are dedicated to providing leading innovations and solutions for today and the future.
Theratechnologies is a specialty pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including those living with HIV.
Theratechnologies
Biolegend
BioLegend is a leading developer of cutting-edge antibodies and reagents provided for biomedical research worldwide. Their objective is to accelerate research and discovery by offering the highest quality products at an outstanding value, along with superior customer service and technical support.
Affiliated Universities & research centers
